No Data
No Data
Oppenheimer's Best 'SMID-cap' Ideas for 2024
Better GLP-1 Biotech Stock: Altimmune Vs. Viking Therapeutics
Small, Mid-size Biotechs Could See M&A Action in H2 - PwC
Spotlight on Viking Therapeutics: Analyzing the Surge in Options Activity
Investors with a lot of money to spend have taken a bullish stance on Viking Therapeutics (NASDAQ:VKTX).And retail traders should know.We noticed this today when the trades showed up on publicly avail
Study Links GLP-1 Drugs, Metformin to Lower Risk of Certain Cancers
BTIG Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $125
BTIG analyst Justin Zelin maintains $Viking Therapeutics(VKTX.US)$ with a buy rating, and maintains the target price at $125.According to TipRanks data, the analyst has a success rate of 37.8% and a t